Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Aug. 25, 2026 /PRNewswire/ -- Leading securities law firm...
CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for Investors
